In VivoThe 2023 pharmaceutical sales ranking of the top 100 Asian biopharma firms reveals a mix of company-specific and wider performance factors linked to both individual corporate fortunes and the changing
ScripChinese developers of COVID-19 antivirals and vaccines are diverging on whether to stay in the game, underscored by mixed first-half progress against the mutating SARS-CoV-2 virus. The Omicron subvari
ScripBig pharma enters 2023 facing a significant patent cliff that will play out over the next few years. Added to its woes is the US Inflation Reduction Act (IRA), which will allow the US government to ne
In VivoIt was an unusual year for the Scrip 100 rankings as revenues from the sale of vaccines and treatments for COVID-19 skewed the leaderboard in ways that could not have been anticipated before the virus